RTW — RTW Biotech Opportunities Share Price
Last trade - 00:00- $537.14m
- $535.62m
- $4.17m
- 20
- 44
- 77
- 41
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.25 | ||
| Price to Tang. Book | 1.25 | ||
| Price to Free Cashflow | 16.01 | ||
| Price to Sales | 128.79 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1.07% | ||
| Return on Equity | 21.42% | ||
| Operating Margin | -114.21% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.08 | 0.15 | 0.66 | 2.17 | 4.17 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +38.66 | +250 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
RTW Biotech Opportunities Ltd is a Guernsey-based focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. The Company invests in companies developing therapies and technologies that can significantly improve patients' lives. The Company seeks to achieve its investment objective by leveraging the Investment Manager's data driven pipeline of assets to invest in life sciences companies across various therapeutic categories and product types (including genetic medicines, biologics, traditional modalities, such as small molecule pharmaceuticals and antibodies, and medical devices). It intends to create a diversified portfolio of investments across a range of businesses, each pursuing the development of superior pharmacological or medical therapeutic assets to enhance the quality of life and/or extend patient life. The Company's portfolio is managed by RTW Investments, LP.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 2nd, 2019
- Public Since
- October 30th, 2019
- Sector
- Collective Investments
- Industry
- Financials
- Exchange
- London Stock Exchange
- Shares in Issue
- 335,713,649
- Address
- 1st Floor, SAINT PETER PORT, GY1 3JX
- Web
- https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/
- Phone
- +44 1481742642
- Contact
- Stephanie Sirota
- Auditors
- KPMG Channel Islands Limited
Latest News for RTW
Upcoming Events for RTW
RTW Venture Fund Ltd Annual Shareholders Meeting
Half Year 2024 RTW Biotech Opportunities Ltd Earnings Release
Similar to RTW
3i Infrastructure
London Stock Exchange
Aberforth Smaller Companies Trust
London Stock Exchange
Aberforth Split Level Income Trust
London Stock Exchange
Abrdn Asia Focus
London Stock Exchange
abrdn Asian Income Fund
London Stock Exchange
FAQ
As of Today at 23:01 UTC, shares in RTW Biotech Opportunities are trading at $1.60. This share price information is delayed by 15 minutes.
Shares in RTW Biotech Opportunities last closed at $1.60 and the price had moved by +29.55% over the past 365 days. In terms of relative price strength the RTW Biotech Opportunities share price has outperformed the FTSE All Share Index by +21.67% over the past year.
There is no consensus recommendation for this security.
RTW Biotech Opportunities does not currently pay a dividend.
RTW Biotech Opportunities does not currently pay a dividend.
RTW Biotech Opportunities does not currently pay a dividend.
To buy shares in RTW Biotech Opportunities you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.60, shares in RTW Biotech Opportunities had a market capitalisation of $537.14m.
Here are the trading details for RTW Biotech Opportunities:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: RTW
Based on an overall assessment of its quality, value and momentum RTW Biotech Opportunities is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like RTW Biotech Opportunities. Over the past six months, its share price has outperformed the FTSE All Share Index by +13.85%.
As of the last closing price of $1.60, shares in RTW Biotech Opportunities were trading +23.86% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The RTW Biotech Opportunities PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on RTW Biotech Opportunities' directors